Combined PD-L1 and CTLA4 blockade demonstrated a 44% overall response rate in patients with nonpancreatic NEC, while in G1/G2 NET objective responses were infrequent [9,10]. This evidence concerns the gene CTLA4 and neuroendocrine carcinoma.